Distant Lymph Node Metastases From Breast Cancer—Is it Time to Review TNM Cancer Staging?
Menée à partir des données des registres américains des cancers portant sur 2 033 patientes atteintes d'un cancer du sein diagnostiqué entre 2010 et 2014 (âge moyen : 62,03 ans), cette étude de cohorte compare la survie des patientes présentant des métastases ganglionnaires à distance et des patientes présentant des métastatases ganglionnaires supra-claviculaires ipsilatérales
Using the Surveillance, Epidemiology, and End Results (SEER) registries database, Hong Pan et al1 retrospectively analyzed 2033 patients who were diagnosed with breast cancer between 2010 and 2014. Patients were allocated into 3 cohorts, namely the distant lymph node metastases (DLNM) cohort, ipsilateral supraclavicular lymph node metastases (ISLM) cohort, and distant metastases (DLNM excluded) cohort. Their results revealed that 3-year breast cancer–specific survival rate (BCSS) and overall survival (OS) rate were similar between patients in the DLNM and ISLM cohorts. In addition, patients with DLNM did not show worse BCSS (HR, 0.93; 95% CI, 0.64-1.36; P = .72) and OS (HR, 0.81; 95% CI, 0.59-1.10; P = .17), compared with those with ISLM. Therefore, the authors concluded that DLNM of breast cancer may be a regional rather than a metastatic disease. Plus, it was recommended to reestablish the staging criteria for breast cancer, and offer patients with DLNM more aggressive locoregional treatments
JAMA Network Open , commentaire, 2020